Contemporary medical management of left ventricular dysfunction and congestive heart failure.

Contemporary medical management of left ventricular dysfunction and congestive heart failure. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Contemporary medical management of left ventricular dysfunction and congestive heart failure. Abstract Text:

K K Teo,A P Ignaszewski,R Gutierrez,K L Hill,S L Martin,H P Calhoun,D P Humen,T J Montague,

OBJECTIVE: The primary purpose of this review was to address the following question: based on the best available evidence, what should be the current medical management of congestive heart failure (CHF)? DATA SOURCES: The major sources for this review were from searches of the English language literature, including computer and bibliography reviews, of all randomized, controlled clinical trials and overview analyses of positive inotropic agents, preload/afterload reduction agents and beta-blocker medications in CHF. STUDY SELECTION: The number of studies reviewed was approximately 40. The major criterion for selection was that the studies be of CHF patients in randomized controlled clinical trials, particularly with a mortality/survival endpoint. Additional clinical trials of nonmortality endpoints in CHF patients and mortality trials in non-CHF patients were also selected to support possible pathophysiological insights for future CHF trials. DATA EXTRACTION: The data, particularly for the accompanying tables, were initially extracted by a single reviewer using common qualitative guidelines as far as was possible within the different temporal, etiological and geographic frameworks of the original component studies. Conclusions are drawn from this data synthesis and from published overviews. DATA SYNTHESIS: Angiotensin converting enzyme (ACE) inhibition therapy is effective in reducing mortality and morbidity in severe left ventricular dysfunction and CHF. Other systemic vasodilators may also be beneficial. The effects of digitalis on survival and morbidity in CHF are presently uncertain, but should be resolved in the near future. Other inotropic agents, at least in the long term, are clinically detrimental. Diuretics decrease morbidity, but their effect on mortality in CHF remains unknown. Beta-blocker and magnesium therapy offer promise in CHF, but await definitive clinical trials evaluation. CONCLUSIONS: The current medical therapy of CHF should definitely include ACE inhibitors, probably diuretics and possibly other vasodilators. Further viable trials of promising new, and older heretofore under-evaluated, CHF therapies are needed. Additionally, innovative strategies are needed to deal with this disease which has an increasing prevalence. Two strategies, primary prevention of CHF and a 'Heart Function Clinic', are discussed.

Contemporary medical management of left ventricular dysfunction and congestive heart failure. Publishing Authors By Initials

KK Teo,AP Ignaszewski,R Gutierrez,KL Hill,SL Martin,HP Calhoun,DP Humen,TJ Montague,

For similar circulatory and respiratory physiology: cardiovascular physiology: cardiovascular physiologic processes: ventricular function: ventricular function, left research abstracts see: circulatory and respiratory physiology: cardiovascular physiology: cardiovascular physiologic processes: ventricular function: ventricular function, left research

PUBMED ID PMID:

MEDLINE DATE:

Contemporary medical management of left ventricular dysfunction and congestive heart failure. Journal Published:

PUBLICATION TYPE: Review

Journal: The Canadian journal of cardiology

VOLUME: 8

Page Numbers: 611-9

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: 04

YEAR: 2008

Contemporary medical management of left ventricular dysfunction and congestive heart failure. Information

Number of References: 42

LANGUAGE: eng

NlmUniqueID: 8510280

Contemporary medical management of left ventricular dysfunction and congestive heart failure. Keywords Mesh Terms:

KEYWORDS: Ventricular Function, Left

MESH TERMS: physiology

Chemical & Substance for Abstract: Contemporary medical management of left ventricular dysfunction and congestive heart failure. Information

Substance Name: Hydralazine

Registry Number: 86-54-4

Grant and Affiliation Information for Contemporary medical management of left ventricular dysfunction and congestive heart failure.

AFFILIATION: Epidemiology Coordinating and Research (EPICORE) Centre, University of Alberta, Edmonton.

Country: CANADA

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Contemporary medical management of left ventricular dysfunction and congestive heart failure Related Publications

• Cause-specific noncardiac mortality in patients with congestive heart failure--a contemporary Canadian audit. Clinical Quality Improvement Network (CQIN) Investigators.
• Clinical efficacy of emergency bypass surgery for failed coronary angioplasty.
• Contemporary disease management in Quebec.
• Contemporary medical management of left ventricular dysfunction and congestive heart failure.
• Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
• Elective irradiation with the electron beam after mastectomy for breast cancer.
• Electromagnetic implantable middle ear hearing device of the ossicular-stimulating type: principles, designs, and experiments.
• Geriatric aspects of rectal diseases.
• Home training for preschool deaf children through correspondence.
• Human ecchordosis physaliphora and chick embryonic notochord. A comparative electron microscopic study.
• In vivo skeletal muscle metabolism during dynamic exercise and recovery: assessment by nuclear magnetic resonance spectroscopy.
• Long term clinical outcomes following isolated mitral valve replacement.
• Long term follow-up after isolated aortic valve replacement.
• Malignant masses in the therapeutically irradiated breast.
• Metabolism of normal skeletal muscle during dynamic exercise to clinical fatigue: in vivo assessment by nuclear magnetic resonance spectroscopy.
• Neural signature of fictive learning signals in a sequential investment task.
• Nonpharmacologic treatment of erectile dysfunction.
• Nonrheumatic atrial fibrillation: a brief overview.
• Optimizing healthcare at the population level: results of the improving cardiovascular outcomes in nova scotia partnership.
• Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy.
• Proceedings: Radiotherapy of breast cancer: guidelines according to features of disease.
• Q-wave infarction: pathophysiology of body surface potential map and ventriculographic patterns in anterior and inferior groups.
• Quantitative relation of electrocardiographic and angiocardiographic measures of risk in patients with coronary atherosclerosis. Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Investigators.
• Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
• Recognition memory as a function of encoding strategy and stimulus codability.
• Short-term memory traces for action bias in human reinforcement learning.
• The changing clinical profile of coronary artery bypass graft patients, 1970-89.
• The first wave.
• The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? The Clinical Quality Improvement Network (CQIN) Investigators.
• The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital.